| Description |
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes[1].
|
| Related Catalog |
|
| Target |
Glucokinase[1]
|
| In Vivo |
Dorzagliatin (low-dose 10 mg/kg, and high-dose 30 mg/kg; administered intragastrically; daily 8:00 AM for one month) exerts a glucose-lowering effect on the glucose levels in diabetic rats[2. Animal Model: Male Sprague-Dawley (SD) rats (aged approximately 6–8 weeks and weighing 200-230 g)[2 Dosage: Low-dose (10 mg/kg), and high-dose (30 mg/kg) Administration: Administered intragastrically (i.g.); daily (8:00 AM) for one month Result: Exerted a glucose-lowering effect on the glucose levels.
|
| References |
[1]. Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab. 2018 Sep;20(9):2113-2120. [2]. Wang P, et al. Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus. J Diabetes Res. 2017;2017:5812607.
|
